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Abstract
Background: The bronchial microbiome in chronic lung diseases presents an abnormal pattern, but its microbial
composition and regional differences in severe asthma have not been sufficiently addressed. The aim of the study
was to describe the bacterial community in bronchial mucosa and secretions of patients with severe chronic
asthma chronically treated with corticosteroids in addition to usual care according to Global Initiative for Asthma.
Bacterial community composition was obtained by 16S rRNA gene amplification and sequencing, and functional
capabilities through PICRUSt.
Results: Thirteen patients with severe asthma were included and provided 11 bronchial biopsies (BB) and 12 bronchial
aspirates (BA) suitable for sequence analyses. Bacteroidetes, Firmicutes, Proteobacteria and Actinobacteria showed relative
abundances (RAs) over 5% in BB, a cutoff that was reached by Streptococcus and Prevotella at genus level. Legionella
genus attained a median RA of 2.7 (interquartile range 1.1–4.7) in BB samples. In BA a higher RA of Fusobacteria was
found, when compared with BB [8.7 (5.9–11.4) vs 4.2 (0.8–7.5), p = 0.037], while the RA of Proteobacteria was lower in BA
[4.3 (3.7–6.5) vs 17.1 (11.2–33.4), p = 0.005]. RA of the Legionella genus was also significantly lower in BA [0.004 (0.001–0.02)
vs. 2.7 (1.1–4.7), p = 0.005]. Beta-diversity analysis confirmed the differences between the microbial communities
in BA and BB (R2 = 0.20, p = 0.001, Adonis test), and functional analysis revealed also statistically significant
differences between both types of sample on Metabolism, Cellular processes, Human diseases, Organismal
systems and Genetic information processing pathways.
Conclusions: The microbiota in the bronchial mucosa of severe asthma has a specific pattern that is not accurately
represented in bronchial secretions, which must be considered a different niche of bacteria growth.
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Background
The respiratory microbiome plays a role in the etiology
and pathogenesis of lung diseases, and a thorough
characterization of the microbial communities in relevant
spatial niches of the respiratory system is needed for the
understanding of their complex interactions [1–4]. Studies
focusing on the respiratory microbiome in chronic re-
spiratory diseases characterized by chronic airway inflam-
mation, such as chronic obstructive pulmonary disease
(COPD), cystic fibrosis (CF) and asthma have reported
clear-cut differences in the composition of the microbial
community with regard to healthy individuals, with an in-
creased presence of members of the Proteobacteria
phylum [5–7]. These changes are probably related to the
structural and functional modifications of the respiratory
mucosa which characterize these diseases and are modu-
lated by the repeated corticosteroid and antibiotic treat-
ments received by most of these patients [8–11].
The respiratory tract extends from the nasal and oro-
pharyngeal cavities to the alveoli and includes niches
with specific patterns in their microbiome composition
[12, 13]. Microbiome studies of the respiratory system
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have been based until now on bronchoalveolar lavage
(BAL), which samples the lower bronchi, and is consid-
ered representative of the bronchial mucosa [14], and
sputum, a non-invasive proximal sample which com-
prises mainly bronchial secretions [14–17]. The compos-
ition of the respiratory microbiome in the upper and
lower respiratory tree is very similar in the healthy subject
[18], but spatial heterogeneity of the bacteria community
within bronchi and lung has been reported in COPD and
CF [2, 19], supporting the hypothesis that the respiratory
system has significant regional differences in its microbial
composition in patients with chronic respiratory diseases.
In addition, bacteria often grow in biofilms, which are
microbial sessile communities embedded in a matrix of
extracellular polymeric substances produced by the bac-
teria that remain attached to host interfaces [20]. Bacteria
in biofilm show an altered growth rate and gene transcrip-
tion phenotype compared with the same microorganisms
growing planktonically [20, 21] and are protected against
host clearance mechanisms and antibiotic therapy [20].
Studies of the respiratory microbiome using culture-
independent techniques in asthma have mainly described
the microbial composition of the bacterial community re-
covered from sputum, but knowledge of the microbiome
lodged in the bronchial mucosa and its functional charac-
teristics is incomplete [7, 22, 23].
Most research on the respiratory microbiome has tar-
geted chronic diseases other than asthma, and the bac-
terial communities living in the bronchial mucosa in
severe asthma are largely unknown. Furthermore, a thor-
ough analysis of different samples may provide a clear
characterization of the bacterial communities living in
different niches of the respiratory tract, which may in-
clude bacteria uncommonly found in bronchial secre-
tions in the healthy subject, which may have an impact
in the progression of the disease. The aim of this study
was to describe the bacterial community lodged in the
bronchial mucosa and in respiratory secretions, as well
as their functional capabilities, in patients with severe
chronic asthma receiving long-term oral corticosteroid
treatment. Differences in the bacterial microbiota be-
tween biopsy samples obtained from a subsegmentary
bronchus and simultaneously recovered bronchial aspi-
rates, which represent bronchial secretions, were
assessed in order to determine the regional distribution




This cross-sectional study was part of a project whose
objective was the characterization of the bronchial tree
in severe IgE-mediated chronic asthma, and included pa-
tients who were members of a cohort regularly attending
an asthma outpatient clinic in a university hospital [24].
Patients were categorized as step 5 for therapy, according
to the Global Initiative for Asthma (GINA, http://ginasth-
ma.org/), and were receiving oral corticosteroids to con-
trol their disease in addition to the usual standard care.
Monoclonal antibody therapy with omalizumab had not
been used in the treatment of the patients at inclusion.
The present study focused on the microbiological charac-
teristics of the bronchial mucosa, and included the assess-
ment of the bronchial microbiome in bronchial biopsies
and aspirates obtained through bronchoscopy. Exclusion
criteria included previously diagnosed bronchiectasis or
cystic fibrosis, an exacerbation and/or a hospital admis-
sion due to any cause within the previous 3 months, and
any other severe disease needing regular therapy. Partici-
pants were examined after a minimum stability period of
12 weeks without using antibiotics for any reason or any
changes in their regular treatment.
Sociodemographic and clinical measurements
Sociodemographic and clinical data were recorded at en-
rollment, and included smoking habits, respiratory symp-
toms, exacerbations in the previous year and treatments.
All patients performed forced spirometry and reversibility
testing according to standard techniques [25]. Forced vital
capacity (FVC) and forced expiratory volume in the first
second (FEV1) were measured with the same dry rolling
seal spirometer (Sibelmed, Sibelgroup, Barcelona, Spain)
and expressed as absolute values (mL) and percentages
of the reference values obtained from age- and height-
adjusted selected volunteers from the province of
Barcelona [26].
Bronchoscopy and sample collection
Bronchoscopy was performed using a flexible video-
bronchoscope (BF180; Olympus Optical Co., Tokyo, Japan).
Local anesthesia and sedation for the procedure were
achieved using topical lidocaine spray and intravenous mid-
azolam respectively, in accordance with standard recom-
mendations [27, 28]. The bronchoscope, after its standard
disinfection procedure, was introduced transnasally and
passed through the vocal cords without aspiration to avoid
contamination of the collected sample by oropharyngeal
bacteria [18]. The bronchial tree was examined and a bron-
chial biopsy (BB) was performed at subsegmentary level on
a bronchus that was macroscopically normal on white light
examination. A bronchial aspirate (BA) was obtained
during the procedure with the tip of the bronchoscope
placed at the distal trachea and main bronchi.
DNA extraction
BB samples were diluted with PBS and centrifuged at
15,000 g for 15 min. The pellet was digested with pro-
teinase K overnight at 56 °C. BA samples were diluted in
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a volume 4 times the weight of the sample with a 1/10
dithiothreitol dilution (Sputasol, Oxoid, Hampshire,
United Kingdom), incubated at 37 °C for 15 min, and
centrifuged at 15,000 g for 15 min. Then, BB and BA
samples were lysed with the same in-house lysis buffer,
which composition has been previously detailed [16] and
consists of 100 U/mL of mutanolysin, 47,700 U/mL of
lysozyme and 2 U/mL of lysostaphin dissolved in
autoclave-sterilized MiliQ water and sterilized again in
autoclave. After cell lysis, different extraction kits were
chosen to purify the DNA from BB and BA samples to ob-
tain the highest DNA yield from each type of sample.
DNA from BB samples was purified with Qiamp MinElute
Virus Spin Kit (Qiagen, Helden, Germany), according to
manufacturer’s instructions, and DNA from BA was puri-
fied with DNA extraction Kit (Ambion, ThermoFisher,
MA, USA), following the manufacturer’s instructions.
DNA was stored at −80 °C for further analysis.
PCR amplification and sequencing of 16S rRNA gene
16S was amplified following the 16S Metagenomic
Sequencing Library Preparation Illumina protocol (Part
# 15044223 Rev. A, Illumina, CA, USA). The gene-
specific sequences used in this protocol target the 16S
V3 and V4 region. Illumina adapter overhang nucleotide
sequences were added to gene-specific sequences, and
primers were selected following Klindworth et al. [29].
Using the standard IUPAC nucleotide nomenclature, the
full length primer sequences used to follow the protocol
targeting this region were: 16S Forward primer = 5′-
tcgtcggcagcgtcagatgtgtataagagacagcctacgggnggcwgcag-3′
and reverse primer = 5′- gtctcgtgggctcggagatgtgtataaga
gacaggactachvgggtatctaatcc-3′.
Microbial Genomic DNA (5 ng/μl in 10 mM Tris
pH 8.5) was used to initiate the protocol. PCR condi-
tions were 5 min of initial denaturation at 94 °C followed
by 25 cycles of denaturation (30 s at 94 °C), annealing
(30 s at 52 °C) and elongation (1 min at 72 °C). After
amplification, the products were visualized in 2% agarose
gels. Extraction controls were PCR amplified in parallel
with the samples, and, although no bands were detected
in the gel electrophoresis, were sequenced together with
the samples. After 16S amplification, the multiplexing
step was performed using Nextera XT Index Kit (FC-
131-1096, Illumina). One microliter of the PCR product
was run on a Bioanalyzer DNA 1000 chip (Agilent, CA,
USA) to verify the size, with an expected size of
~550 bp. After size verification, the libraries were
sequenced using a 2 × 300 bp paired-end run (MiSeq
Reagent kit v3 MS-102-3001, Illumina), on a MiSeq
Sequencer according to manufacturer’s instructions
(Illumina).
Quality assessment was performed by the use of the
PRINSEQ-lite program [30] with the following parameters:
min_length: 50, trim_qual_right: 20, trim_qual_type: mean,
trim_qual_window: 20. R1 and R2 from Illumina sequen-
cing were joined using fastq-join from ea-tools suite [31].
Sequence analysis and microbiome accession number
The Quantitative Insights Into Microbial Ecology (QIIME)
pipeline 1.9.0 [32] was used for sequence processing to
obtain taxonomic information using the Greengenes 13_8
sequence database as reference and the RDP classifier 2.2.
The open reference operational taxonomic unit (OTU)
picking method was used with UCLUST and PyNAST ver-
sion 1.2.2 as alignment method. Chimeric sequences were
detected in QIIME with ChimeraSlayer and were removed
from the OTU table and from the phylogenetic tree to
perform downstream analyses.
In order to assess the influence of the reagent contam-
ination in our samples, we sequenced 4 extraction con-
trols and 1 PCR negative control. We obtained a mean
of 633 (SD 469) sequences in these controls, which were
processed in QIIME, the same way than the samples.
Sixty-four different genera from 11 eleven phyla were
identified in the negative controls, 37 of them with rela-
tive abundance >1% in at least one sample.
Following Bitiinger et al. [33] Fisher exact test was used
to compare the overall frequency of occurrence of each
genus between samples and controls. Genera showing in
controls relative abundances (RAs) exceeding that in sam-
ples were considered as potential contaminants and were
removed for subsequent analyses, and common contamin-
ant genera were also checked in the samples and eliminated
when present [34]. After removing all the contaminant
OTUs from the final OTU table, downstream analyses were
performed to determine alpha and beta-diversity.
Bacterial 16S rRNA data sets from this study are access-
ible in the European Nucleotide Archive under the study
PRJEB12006 with the sample numbers ERS1014176-199.
Functional analysis
The PICRUSt (Phylogenetic Investigation of Communi-
ties by Reconstruction of Unobserved States) software
package [35] was used for the predictive functional ana-
lysis. This software estimates the community metagen-
ome using 16S rRNA sequencing data. KEEG (Kyoto
Encyclopedia of Genes and Genomes) pathway [36] was
used to identify metagenomic contents. Abundance pro-
files of functional annotations were obtained and differ-
ences in the functional genomic content were evaluated
after normalizing the abundances of each category to the
total number of proteins predicted for each sample [37].
Statistical analyses
Statistical analyses were performed using the SPSS
statistical software package version 18 (SPSS Inc., Chicago,
IL, USA). Results obtained from categorical variables are
Millares et al. BMC Microbiology  (2017) 17:20 Page 3 of 11
expressed as absolute and relative frequencies, and results
for continuous variables as means and standard deviations
(SD), when the distribution was normal or as medians and
interquartile range (IQR) when the distribution was not
normal. Bacterial α-diversity was assessed through the
Chao1 estimator [38] and the Shannon index [39],
calculating both indexes after subsampling with QIIME to
avoid sequencing effort bias. Principal Coordinates
Analysis (PCoA) with Bray-Curtis dissimilarity index [40]
was used to study community composition, assessing the
statistical significance of the differences in sample group-
ings through Adonis testing. Random forest analysis with
Boruta feature selection was used to select the specific
OTUs that were important in each type of sample using R
package (http://www.r-project.org). Functional categories
and their RA in both samples were compared using the
Wilcoxon test. Statistical tests used in the study were




Thirteen patients with severe asthma were included in
the study and provided 11 BB and 12 BA suitable for
sequence analyses. Eight patients were women and five
men with a mean age of 49 years (SD 14) and a FEV1 of
74% (SD 18.6). All had been receiving chronic treatment
with oral corticosteroids for the control of their disease
for a minimum period of 1 year.
16S rRNA analysis in BB samples
In BB samples, six phyla showed a RA over 1%: Bacter-
oidetes [median 34.1 (interquartile range (IQR) 20.2–
37.3)], Firmicutes [27.9 (20.9–35.1)], Proteobacteria
[19.1 (12.1–30.1)], Actinobacteria [7.8 (6.4–11.2)],
Fusobacteria [4.3 (0.8–7.2)] and TM7 [1.1 (0.4–3.1)]. At
genus level, this 1% cutoff was reached by 17 genera
with Streptococcus [12.3 (2.3–15.7)] and Prevotella
[11.4 (1.6–16.3)] being the most prevalent (Additional
file 1: Table S1). Legionella and Haemophilus genera
were found in all BB samples with median RA above
2% [2.7 (1.1–4.8) and 2.1 (0.6–4.1) respectively], while
Pseudomonas genus was only found with median RAs
below 1% [0.9 (0.3–1.9)] (Table 1).
Comparison between bronchial aspirate (BA) and biopsy
(BB) samples
In order to compare BA and BB 10 paired samples from
the studied patients were used. The bacterial composition
of BA samples showed statistically significant differences
from BB at both phylum and genus levels. Bacteroidetes
[36.1 (26.9–40.1)], Firmicutes [38.8 (32.3–44.2)], Proteo-
bacteria [3.7 (3.7–6.5)], Actinobacteria [8.7 (6.9–12.6)],
Fusobacteria [8.7 (5.9–11.4)], and TM7 [1.2 (0.2–3.1)]
attained median RAs over 1% in BA, similarly found in
BB. Fusobacteria, however, showed significantly higher
RAs in BA [8.7 (5.9–11.4) vs 4.2 (0.8–7.5), p = 0.037,
Wilcoxon test], while the RA of Proteobacteria was signifi-
cantly lower in BA when compared with BB [4.3 (3.7–6.5)
vs 17.1 (11.2–33.4), p = 0.005, Wilcoxon test] (Table 2).
At genus level, higher RAs were found in BA for 28 gen-
era, nine of them with median RAs over 1%, and among
them Prevotella and Streptococcus attained levels over
20%. In BB, significantly higher RAs were found for 48
genera, with figures over 1% in 9 of them, including Le-
gionella genus, which was only exceptionally found in BA.
Overall, 76 out of 280 identified genera showed significant
differences between BA and BB samples (Table 3).
Table 1 Genera with median relative abundances >1%



















Table 2 Differences in the relative abundances of the phyla
detected in BB and BA samples with median >1% at least in
one type of sample
Phylum BB (n = 10) BA (n = 10)
Median (IQR) Median (IQR) p value
Bacteroidetes 34.4 (19.8–38.7) 36.1 (26.9–40.1) 0.799
Firmicutes 26.2 (20.2–36.4) 38.8 (32.2–44.1) 0.074
Proteobacteria 17.1 (11.2–33.4) 4.3 (3.7–6.5) 0.005
Actinobacteria 7.5 (6.3–11.3) 8.7 (6.9–12.6) 0.139
Fusobacteria 4.2 (0.8–7.5) 8.7 (5.9–11.4) 0.037
TM7 1.4 (0.3–3.1) 1.2 (0.2–3.1) 0.878
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Regarding bacterial α-diversity, Chao1 richness
parameter did not show differences between BA and
BB samples [2056.1 (1388.2–2517.2) vs. 1971.4
(1540.1–2217.1), p = 0.575, Wilcoxon test] and Shan-
non index, which combines both richness and even-
ness, was slightly lower in BA samples [5.7 (5.1–5.9)
vs. 6.9 (5.7–7.3), p = 0.059, Wilcoxon test] (Fig. 1).
This difference, although not statistically significant,
suggests that the bacterial community had dominant
taxa in BA. The assessment of the microbial com-
position using sample grouping at PCoA and the
Bray-Curtis dissimilarity index showed also differ-
ences between BA and BB samples (Fig. 2), and
Adonis testing confirmed that the microbial compos-
ition differed in both samples (R2 = 0.21, p = 0.001).
Random forest analysis with Boruta feature selection
Table 3 Genera with median relative abundances higher than 1% at least in one type of sample showing significant differences
between BB and BA (higher abundances in bold types)
Genera Biopsy (BB) (n = 10)
Median (IQR)
Aspirate (BA) (n = 10)
Median (IQR)
p value
Streptococcus 10.9 (2.2–15.8) 24.2 (13.7–28.1) 0.007
Prevotella 12.2 (3.5–17.3) 23.3 (12.1–26.9) 0.037
Flavobacteriaceae_g 2.8 (0.6–5.7) 0.04 (0.007–0.08) 0.005
Legionella 2.7 (1.1–4.7) 0.004 (0.001–0.02) 0.005
Fusobacterium 2.5 (0.8–5.7) 4.9 (2.9–7.5) 0.047
Staphylococcus 1.8 (0.4–3.5) 0.04 (0.02–0.3) 0.005
Cloacibacterium 1.8 (0.3–3.7) 0 (0–0.0006) 0.005
Legionellaceae_g 1.6 (0.5–2.7) 0.004 (0.0002–0.02) 0.005
Chryseobacterium 1.3 (0.3–2.8) 0.01 (0.002–0.03) 0.005
Gemellaceae_g 1.5 (0.1–3.3) 3.4 (2.3–4.6) 0.037
Lactobacillus 1.2 (0.07–2.1) 0.02 (0.002–0.06) 0.005
Corynebacterium 1.04 (0.5–2.8) 0.2 (0.1–0.4) 0.005
Acinetobacter 1.03 (0.04–3.02) 0.005 (0.0008–0.01) 0.005
Leptotrichia 0.8 (0.2–2) 3.3 (2.3–4.6) 0.005
Rothia 1.01 (0.2–2.2) 3.1 (1.8–7.6) 0.007
Actinomyces 0.7 (0.4–1.3) 2.7 (0.9–3.7) 0.017
Atopobium 0.6 (0.1–1.3) 1.4 (0.8–2.3) 0.028
Megasphaera 0.8 (0.04–0.9) 1.4 (0.8–2.6) 0.022
Fig. 1 Chao1 index as a measure of richness and Shannon index as a measure of both richness and evenness in bronchial biopsy and aspirate
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identified 25 highly representative OTUs, four
present only in BA samples and 21 with higher
abundance in BB (Fig. 3). These OTUs were able to
discriminate between BB and BA samples, and classi-
fied 11 out of 12 samples as BA and 10 out of 11
samples as BB.
Functional analysis with PICRUSt
The PICRUSt program was used to predict the func-
tional capacities of the bacterial community from 16S
rRNA sequences. From the six categories that make
up KEGG level1, Genetic information processing was
the only category which showed higher abundance in
BA samples [22.3 (21.9–22.5) vs 18.1 (16.9–21.5), p =
0.017, Wilcoxon test], while Metabolism, Cellular pro-
cesses, Human diseases and Organismal systems were
significantly more abundant in BB [48.3 (47.9–48.9)
vs 47.5 (46.9–47.7), p = 0.017; 3.1 (1.9–3.5) vs 1.7
(1.6–1.8), p = 0.009; 1.1 (0.9–1.1) vs 0.8 (0.8–0.9), p =
0.005 and 0.7 (0.6–0.8) vs 0.6 (0.6–0.6), p = 0.028
respectively] (Fig. 4). At KEGG level 2, 35 functional
categories were detected, 24 with significant differences
in their RA between BB and BA samples, nine higher in
BA and 15 in BB (Fig. 5).
Fig. 2 PCoA plot with Bray-Curtis β-diversity parameter. Biopsy samples in grey and aspirate samples in black
Fig. 3 OTUs that discriminate between bronchial biopsy and aspirate, according to random forest analysis with boruta feature selection. Biopsy
samples in grey and aspirate samples in black
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Discussion
In this study we assessed the bacterial composition of the
bronchial mucosa in severe chronic IgE-mediated asthma
patients. Bacteroidetes, Firmicutes, Proteobacteria and
Actinobacteria were the most abundant phyla, and Prevo-
tella and Streptococcus the most predominant genera.
Bacteria from Legionella genus were widely present in
bronchial biopsies from severe asthma and attained RAs
over 2% in most patients. Bronchial secretions showed a
similar richness but clear-cut differences in their microbial
composition, partly due to an overrepresentation of
microorganisms from Bacteroidetes and Firmicutes phyla.
These results confirm that the bronchial mucosa harbor a
specific bacterial community in severe IgE-mediated
chronic asthma, that is only partially represented by the
microbiota of bronchial secretions.
Fig. 4 PICRUSt results at KEGG level 1. BB samples in grey and BA in black. Functional categories with significantly higher levels in BB (*) and BA
(+) samples
Fig. 5 PICRUSt results at KEGG level 2. BB samples in grey and BA in black. Functional categories with significantly higher levels in BB (*) and BA
(+) samples
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In the present study, Bacteroidetes, Firmicutes and
Proteobacteria phyla reached RAs over 15% in the bron-
chial mucosa of severe asthma patients, with Streptococcus
and Prevotella, which attained RAs over 10%, as the most
predominant genera. Proteobacteria phylum had signifi-
cantly higher RA, a pattern that has been also reported for
other severe chronic respiratory diseases such as COPD
and CF [6, 8, 9], suggesting a common dysbiotic pattern in
these obstructive diseases. The respiratory microbiome in
healthy subjects is composed mainly of bacteria present in
the oropharynx which migrate to the bronchial tree
through aspiration and are found in the bronchial mucosa
at low loads [13, 14, 41]. In subjects with chronic obstruct-
ive lung diseases such as COPD and CF, the structural and
functional changes in the microenvironment conditions of
the respiratory tract lead to a modification of their bacter-
ial composition [41]. These changes favor an overgrowth
of specific bacteria, mainly from the Proteobacteria
phylum, which turn out to be well-adapted to the charac-
teristics of the new environment, and is paralleled by a
decline in the microbial diversity [17, 42]. This change is
especially evident in patients with more severe disease,
who show further increases in Proteobacteria and high
levels of specific genera such as Pseudomonas [2, 8].
Despite the fact that our results confirm the increase of
Proteobacteria abundance in bronchial mucosa, previously
reported in asthma patients [6, 43], our patients did not
show an overrepresentation of the genera Haemophilus
and Pseudomonas, which is a frequent characteristic of
severe COPD patients, and confirms that bronchial micro-
biome changes have specific patterns in severe asthma,
also supported by the extensive identification of high loads
of microorganisms from Legionella genus in the patients
studied. These differences could be partially explained by
tissue changes often observed in bronchial asthma and
less frequent in COPD, such as an increase in tissue repair
patterns [44].
Our results demonstrate that in asthma patients the
microbiota recovered from bronchial secretions shows
differences from the microbiota harbored in the bron-
chial mucosa. Firmicutes and Bacteroidetes had RAs
over 25% in both BB and BA samples and were the most
abundant phyla in both samples, but Proteobacteria
phylum, which attained RAs over 15% in BB samples,
was significantly less abundant in BA. At genus level,
Prevotella and Streptococcus were the most abundant in
both samples, although their proportions differed signifi-
cantly in bronchial aspirates and biopsies. These two
genera represented nearly a quarter of the RA of all the
observed microbiota in BA samples, while in BB samples
only accounted for slightly over 10% of the abundance.
This finding is in agreement with α-diversity results, as
shown by the Shannon index, which measures both
richness and evenness, which was slightly lower in BA
samples. Evenness is low in communities dominated by
only a few species, and higher when the abundance is
distributed equally among the wide range of species
present in the sample. The differences observed in the
bacterial communities of BA and BB samples were also
found in the PCoA analysis performed. Studies of the
bronchial microbiome of asthma patients have been based
until now on bronchial brushings or bronchoalveolar lavage
[6, 15, 43], which are considered representative of the bron-
chial mucosa on the basis of the results obtained in healthy
subjects and COPD patients [14, 45], and in sputum sam-
ples [7, 22, 23]. The existence of substantial differences in
the microbiota of bronchial secretions, sampled either
through sputum or BA, and the bronchial mucosa confirms
that these compartments should be considered to be
different in patients with severe allergic chronic asthma,
and supports the hypothesis that some of the microbial
characteristics of the bronchial mucosa will be missed when
only bronchial secretions are sampled in chronic respiratory
diseases.
The presence in biopsy samples of biofilm-associated
bacteria, such as Pseudomonas [21, 46, 47] and Legion-
ella [48, 49], suggests that biofilm may be present on the
bronchial mucosa of severe chronic asthma patients.
Bacteria with the ability to form biofilms develop sessile
communities which show major differences with respect
to free-floating bacteria [21, 50]. BB appears to identify
bacteria potentially embedded in biofilm and harbored in
the bronchial mucosa, while BA samples seems to contain
a major proportion of microorganisms with planktonic
growth. Previous results of studies of the gastrointestinal
tract have also shown that the microbiota of feces is not
representative of the bacterial community of the gastro-
intestinal mucosa [51, 52]. The results obtained in respira-
tory samples from our study confirm that these differences
in the bacterial composition between mucosa and luminal
samples are not exclusive to the gut, and may be considered
part of a pattern that includes the respiratory system.
The extensive finding of genus Legionella in the bron-
chial mucosa of severe allergic chronic asthma patients
was unexpected. This genus was present in all BB samples
where reached a median RA of 2.7%, and was significantly
lower in BA samples. The identification of sequences with
the Greengenes database was checked by aligning the se-
quences in BLAST and SINA [53], which confirmed the
identification of all sequences as Legionella. To our know-
ledge, the presence of this genus in the bronchial mucosa
of patients with chronic respiratory diseases such as
asthma has not been previously reported, and future
studies focusing on its role in patients following regular
treatment with corticosteroids will be needed. Legionella
species have been identified in non-malignant lung tissue
obtained from lung cancer patients who underwent su-
rgical resection [54], a finding in agreement with the
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hypothesis that Legionella may persist in human cells,
against the common criteria that these microorganisms
may be only found in patients with acute respiratory
symptoms. Legionella is able to replicate intracellularlly in
macrophages that have phagocytized aerosolized bacteria,
and several studies have shown that Legionella pneumo-
phila creates endoplasmic reticulum (ER)-like vacuoles that
support intracellular replication. Through this mechanism
the bacteria are able to interfere host autophagy processes,
which is an ancient cell autonomous defense pathway based
on ER-derived membranes to target intracellular pathogens
for destruction [55–58]. The presence of Legionella in our
BB samples could be explained by this mechanism, but
future studies focused on the chronic presence of these
bacteria in the respiratory system will be needed to confirm
these findings and their medical implications.
Functional analysis using PICRUSt showed clear differ-
ences between the bacterial predicted metabolic functions
in each type of sample in our study. Cellular Processes,
Metabolism, Organismal Systems and Human Diseases
pathways were significantly more abundant in bronchial
tissue, while the Genetic Information and Processing
pathway was more frequent in bronchial secretions. These
findings seem also to be in accordance with previous
studies showing that the gene expression of bacteria
growing in biofilms differs from that of bacteria growing
planktonically [20]. Biofilm bacteria have a specific growth
rate and are more metabolically active [21], and the results
obtained support the hypothesis of a wider metabolic ac-
tivity of the microbiome found on the bronchial mucosa,
identifiable through functional metagenomics.
The present study has some limitations that should be
taken into account. First of all, the sample size was
limited to 13 severe IgE-mediated chronic asthma pa-
tients; the inclusion of more subjects in future studies
will be needed to confirm our results. Secondly, the pa-
tients enrolled had severe allergic asthma and were
treated with oral corticosteroids, and the results ob-
tained may not be extrapolable to patients with moder-
ate asthma or patients who do not need chronic oral
corticosteroid treatment. Thirdly, aspirate and biopsy
samples are different approaches to sampling, and larger
lung regions are sampled by aspirates. Therefore, the
differences we obtained may be due to the method of
sampling. Finally, we chose DNA purification method-
ologies to be used in every type of sample in order to
obtain the maximum sample yield, a required approach
for low biomass samples, as bronchial biopsies and aspi-
rates, and we can not discard a marginal influence of the
purification procedures followed on the obtained results.
Conclusions
In severe chronic asthma there is high presence of
Proteobacteria phylum in the bronchial mucosa, a microbial
pattern that resembles COPD and CF, but shows specific
findings as an extensive presence of Legionella genus, and
low RAs of the genera Haemophilus and Pseudomonas.
These findings confirm that the similarities between the
bronchial microbiome of chronic obstructive respiratory
diseases are only partial. Dominant taxa and lower evenness
were observed in bronchial aspirates in these patients,
confirming that bronchial secretions are only partially
representative of the microbial communities from the
bronchial mucosa, and confirm the existence of different
niches for bacteria growth in the respiratory tree. Accord-
ingly, the study underlines the inherent difficulties in
obtaining a reliable description of the respiratory micro-
biome of the bronchial mucosa from the analysis of
bronchial secretions.
Additional file
Additional file 1: Table S1. Relative abundance (median, IQR) of all
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